Supplementary Table S3 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>
Anne E. O’SheaGuy T. CliftonNa QiaoBrandy M. Heckman‐StoddardMałgorzata WójtowiczEileen DimondIsabelle BedrosianDiane WeberJudy E. GarberAlexander HusbandRicardo PastorelloJ. Jack LeeMike HernándezDiane D. LiuLana A. VornikPowel H. BrownGheath AlatrashGeorge E. PeoplesElizabeth A. Mittendorf
0
Citation
0
Reference
10
Related Paper
Abstract:
<p>Supplementary Table S3: Pathologic characteristics</p>Keywords:
Peptide vaccine
Table (database)
Carcinoma in situ
Cite
Citations (1)
<p>Supplementary Table S1: Demographics by therapy</p>
Demographics
Table (database)
Peptide vaccine
Cite
Citations (0)
Background: We evaluated the presence of ductal carcinoma in situ (DCIS) in core needle biopsies (CNB) from invasive ductal lesions.Methods: Retrospective study, which analyzed 90 cases of invasive ductal carcinoma lesions.The percentage of DCIS was quantified in each specimens obtained from CNB, which were compared to the surgical specimens.CNB and surgical specimens were evaluated by the same pathologist, and the percentage of DCIS in CNB was evaluated (percentage) and divided into categories.We considered the following parameters regarding the amount of DCIS: 1 = 0; 2 = 1 for 5%; 3 = 6 for 24%; 4 = 25 for 50%; 5 = 51 for 75% and 6 = 76 for 99%.The number of fragments and the histological pattern of DCIS was found.Results: We found the following results regarding the distribution of the percentage of DCIS in the CNB: 1 = 63.3%; 2 = 12.2%; 3 = 12.2%; 4 = 5.6%; 5 = 1.1% and 6 = 5.6%.The logistic regression analysis showed that CNB percentages above 45% reflected the presence of DCIS in the surgical specimen in 100% of the cases (p < 0.001), with a specificity of 100%, accuracy of 83.3% and false positive rate of 0% (p <0.001).Conclusion: There is direct relationship between extensive intraductal component in the surgical specimen when the core biopsy shows 45% or more of the DCI or microinvasive in the material examined.
Carcinoma in situ
Surgical pathology
Cite
Citations (4)
Nuclear pleomorphism is a fundamental feature in evaluating the aggressiveness of ductal carcinoma in situ (DCIS) of the breast. In this study, pure DCIS and the in situ component (IS-comp) of invasive duct carcinoma (IDC) are compared in order to verify if these are two different entities or the same process observed at different times during its evolution. Five cases of pure DCIS and nine of IDC with extensive in situ component were selected. They were moderately and poorly differentiated. 30 nuclei for each DCIS, and 30 nuclei for both the in situ and invasive component of each IDC were studied; thus, a total of 720 nuclei were submitted to the SAM (Shape Analytical Morphometry) analysis, which enables a numerical expression not only of dimensions (area, perimeter, diameter) but also of nuclear contour irregularities and nuclear shape distortions. Univariate statistical comparisons were carried out between the nuclei of: (1) DCIS and in situ component of invasive duct carcinoma, (2) DCIS and the invasive component of infiltrating carcinoma and (3) between the in situ and invasive component of infiltrating carcinoma. Multivariate analysis was utilized to compare nuclei of DCIS with the in situ component of IDC. The in situ features of each tumor were also evaluated with the mitotic index (MI). Nuclei of pure DCIS resulted significantly larger (p < 0.001) and with a more regular shape (p < 0.001) than those of the in situ component of IDC. No differences were observed between the nuclei of the in situ and the invasive component of infiltrating carcinomas. Multivariate statistical analysis discriminated 77% of nuclei of in situ proliferation when both G2 and G3 tumors were considered, and 80% when only G3 tumors were considered. In conclusions morphological differences exist between pure DCIS and the in situ component of IDC, which may be an expression of their biological behavior; moreover, these morphological differences seem to have a better discriminating power within the same histological grade.
Carcinoma in situ
Cite
Citations (14)
Univariate analysis
Carcinoma in situ
Cite
Citations (0)
Carcinoma in situ
Cite
Citations (1)
Cite
Citations (22)
Cite
Citations (0)
<p>Supplementary Table S5: HER2 expression in biopsy and resection specimens</p>
Table (database)
Carcinoma in situ
Cite
Citations (0)
<p>Supplementary Fig. S2: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving GM-CSF alone with corresponding HER2 changes</p>
Peptide vaccine
Carcinoma in situ
Cite
Citations (0)